• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    岐

    岐阜市民病院

    Gifu Municipal Hospital
    EST. 1941
    980论文总数
    1.7万引用总数

    论文量&引用量时间轴

    机构学者

    论文(980)

    年份
    起
    –
    止
    排序
    1Chromatin Landscape and Epigenetic Heterogeneity of Acute Myeloid Leukaemia
    Yotaro Ochi,Markus Liew-Littorin,Yasuhito Nannya,Sofia Bengtzen, Benedicte Piauger,Stefan Deneberg,Martin Jädersten,Vladimir Lazarevic,Jörg Cammenga, Anna Robelius,Lovisa Wennström,Emma Ölander,

    Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML1-8; however, the role of epigenetic alterations in these respects has been investigated less extensively. Here we use ATAC-seq (assay for transposase-accessible chromatin with sequencing) in a cohort of 1,563 individuals with a recent diagnosis of AML (the 'eCHROMA' cohort) to show that AML can be classified into 16 subgroups on the basis of chromatin accessibility profiles. Multiomics analyses of gene mutations, the transcriptome, DNA methylation and histone marks show that these ATAC subgroups exhibit distinct driver mutations, differentiation states, gene expression, DNA methylation and super-enhancer profiles, and are also associated with clinical outcomes. These findings were validated in independent cohorts. Single-cell ATAC sequencing reveals that all leukaemic cells in each subgroup share a common chromatin accessibility profile, which suggests that subgroup-specific epigenomic fingerprints underlie the ATAC-based classification. Mechanistically, the subgroups have distinct gene-regulatory networks that are driven by the activities of key transcription factors in haematopoiesis, and in which subgroup-specific super-enhancers have a pivotal role. Multiomics single-cell analysis further reveals deregulated trajectories of differentiation coupled with chromatin accessibility and gene expression. Notably, ATAC subgroups have an independent prognostic effect, compared with genomic classification, and are associated with particular drug sensitivities. In summary, ATAC-based chromatin profiling, combined with multiomics data, provides insights into AML pathogenesis beyond genomics and constitutes a valuable resource for AML research.

    2026Nature(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2Immediate or On-Demand Endoscopic Necrosectomy for Necrotizing Pancreatitis: A Randomized Controlled Trial (WONDER-01).
    Tomotaka Saito,Toshio Fujisawa,Takeshi Ogura,Masaki Kuwatani,Hiroshi Ohyama,Mamoru Takenaka,Shinpei Doi,Keisuke Iwata,Shinichi Hashimoto,Hideki Kamada,Takuji Iwashita,Hideyuki Shiomi,

    BACKGROUND & AIMS:The optimal timing for direct endoscopic necrosectomy (DEN) after endoscopic ultrasound (EUS)-guided transmural drainage of symptomatic necrotizing pancreatitis remains unknown. We hypothesized that immediate DEN after EUS-guided drainage might reduce the time to disease resolution compared with a drainage-oriented step-up approach. METHODS:This study was a multicenter, open-label, superiority randomized trial (WONDER-01). Among patients who received EUS-guided treatment for symptomatic necrotizing pancreatitis, eligible patients were randomly assigned 1:1 to receive either immediate DEN or the drainage-oriented step-up approach. The primary endpoint was the time from randomization to clinical success, defined as a decrease in collection size to ≤3 cm and an improvement in inflammatory markers. RESULTS:Seventy patients were enrolled in this study: 33 in the immediate DEN arm and 37 in the step-up arm. Immediate DEN was associated with a shorter time to clinical success than the step-up approach (P = .009), with median times (95% confidence interval) of 29 (19-34) and 44 (38-52) days, respectively. All patients in the immediate DEN arm received DEN compared with 46% in the step-up approach arm, but the rates of procedure-related adverse events were comparable (24% vs 22%, respectively; P = .79). No significant differences were noted between the treatment arms in terms of technical success (100% vs 97%; P > .99) and mortality (12% vs 5.4%; P = .41). CONCLUSIONS:Compared with the step-up approach, immediate DEN after EUS-guided drainage of necrotizing pancreatitis reduced time to clinical success without increasing adverse outcomes but required more DEN procedures (ClinicalTrials.gov, NCT05451901).

    2026Gastroenterology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3A Case of Severe Bullous Drug Eruption Resembling Stevens-Johnson Syndrome after Nivolumab and Tegafur-Gimeracil-oteracil Administration with Lymphocytic Infiltration into the Eccrine Ducts and Distinctive Re-Epithelialization Features.
    Keisuke Ueda, Hiromu Tsuji, Anna Sumigama,Naoki Watanabe, Daichi Kodama,Takuji Tanaka,Hiroyuki Kanoh
    2026European journal of dermatology EJD(2026)
    引用
    AI阅读
    加入学术空间
    4[Transient Acquired Thrombotic Thrombocytopenic Purpura Developed During Bortezomib, Lenalidomide, and Dexamethasone Therapy for Multiple Myeloma].
    Takayuki Goto, Junichi Kitagawa, Yuya Sakaida, Ryoma Shimazu, Daisuke Okamoto, Tomomi Suzaki, Kimihiro Yamaguchi,Yuhei Shibata,Hisashi Tsurumi,Senji Kasahara

    A 59-year-old woman was diagnosed with symptomatic Bence Jones protein, lambda (λ) type, associated with multiple myeloma (BJP-λ MM). Considering her renal dysfunction, she initially received bortezomib and dexamethasone. After renal function improved, she received one cycle of bortezomib, lenalidomide, and dexamethasone (BLD) therapy and achieved stringent complete response. She presented with general fatigue and jaundice before the second cycle of BLD. Laboratory testing revealed: total bilirubin, 4.8 mg/dl; indirect bilirubin, 4.1 mg/dl; lactate dehydrogenase, 978 U/l; hemoglobin, 7.4 g/dl; haptoglobin, <10 mg/dl; platelet count, 23,000/µl; and creatinine, 0.96 mg/dl. A hemogram revealed 1% schistocytes. ADAMTS13 activity was undetectable and the ADAMTS13 inhibitor level was 1.8 Bethesda units. A diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) was made, and treatment was initiated with prednisolone and rituximab. Plasma exchange was not performed because thrombocytopenia did not progress. The first dose of rituximab restored platelet count, and ADAMTS13 inhibitor became undetectable. The clinical course in this case was consistent with drug-induced aTTP.

    2026Rinsho ketsueki The Japanese journal of clinical hematology(2026)
    引用
    AI阅读
    加入学术空间
    5Phase III Randomized Controlled Trial to Confirm Efficacy of Surgery Plus Postoperative Dose-Modified S-1 Adjuvant Chemotherapy Against Surgery Alone for Vulnerable Elderly Patients with Pathological Stage II/III Gastric Cancer: JCOG1507 (BIRDIE Trial).
    Itaru Yasufuku,Kazuhiro Yoshida,Kazuya Yamaguchi, Masayuki Yokoyama,Masahide Kaji,Sang-Woong Lee,Yasuhiro Choda,Shinichi Sakuramoto,Naoki Okumura,Hiroshi Katayama,Haruhiko Fukuda,Yukinori Kurokawa,

    347 Background: In Japan, the standard treatment for resectable gastric cancer is primary gastrectomy followed by adjuvant chemotherapy based on S-1. However, the survival benefit of adjuvant chemotherapy in elderly patients, particularly those considered vulnerable, remains uncertain. Methods: JCOG1507 (BIRDIE trial) was a phase III randomized controlled trial to confirm the superiority of dose-modified S-1 adjuvant chemotherapy to surgery alone for vulnerable elderly patients with pathological stage II/III gastric cancer. The trial was conducted at 45 institutions of the Stomach Cancer Study Group of the Japan Clinical Oncology Group. Vulnerability to S-1 was defined as: (1) weight loss <15% and creatinine clearance (Ccr) ≥30 mL/min after total gastrectomy, or (2) weight loss <15% and 30 ≤ Ccr <80 mL/min after the other gastrectomy. Patients in the control arm were followed without S-1, while those in the experimental arm received one year of dose-modified S-1 monotherapy at a reduced dose according to the Ccr and type of gastrectomy. The primary endpoint was overall survival (OS). Secondary endpoints included relapse-free survival (RFS), time-to-treatment-failure, treatment continuity, dose intensity, and safety. Assuming a 3-year OS of 55% in the control arm and a 10% improvement with the experimental arm, the sample size was set at 370 (one-sided α=0.05, power 75%). This trial was registered with UMIN (000025742). Results: Patient accrual began in January 2017, but the planned sample size was reduced to 170 due to slow accrual (α=0.1, power 70%), and enrollment was closed to 167 patients in January 2024. At the second planned interim analysis, conducted after completion of protocol treatment for all enrolled patients on June 21, 2025, the 3-year OS was 63.8% (95% CI, 51.0–74.1) in the control arm and 63.4% (95% CI, 50.6–73.7) in the experimental arm (stratified HR, 1.272; 95% CI, 0.768–2.107). As the probability of demonstrating superiority at the final analysis was considered low, the trial was terminated early due to futility. For RFS, the 3-year RFS was 52.5% (95% CI, 40.6–63.1) in the control arm and 57.9% (95% CI, 45.5–68.4) in the experimental arm (HR, 0.888; 95% CI, 0.567–1.389). Conclusions: Dose-modified S-1 adjuvant therapy did not improve OS in vulnerable elderly patients with pStage II/III gastric cancer. Surgery alone remains the standard treatment for this population. Clinical trial information: 000025742 .

    2026JOURNAL OF CLINICAL ONCOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 980 篇论文

    合作机构(100)

    岐阜大学合作论文 244
    Gifu University Hospital合作论文 179
    Gifu Prefectural General Medical Center合作论文 109
    东京大学合作论文 76
    Ogaki Municipal Hospital合作论文 68
    近畿大学合作论文 59
    北海道大学合作论文 54
    京都大学合作论文 45
    松波病院合作论文 45
    顺天堂大学合作论文 42

    机构统计